TUESDAY, Nov. 26, 2024 (HealthDay News) -- Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but nearly a third of patients can't tolerate its side effects and quit ...

Lee’s team at the Huntsman Cancer Institute reviewed 14 studies, featuring a total of 9,500 patients with head and neck cancer and nearly 15,800 people without cancer, comparing their ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...

Smoking, alcohol consumption and betel nut chewing are some of the lifestyle factors that have been linked to head and neck cancer. In the Philippines, more than 7,000 Filipinos are diagnosed with ...

Head and neck cancer, referring to cancers of the oral cavity, pharynx, larynx, paranasal sinuses and nasal cavity, and salivary glands, is the seventh-most common type of cancer.There are over ...

In the United States, head and neck cancers make up 4% of all cancers, with more than 71,000 new cases and more than 16,000 deaths expected in 2024, according to the National Foundation for Cancer ...

Marijuana users are as much as 5 times more likely to develop head and neck cancers than those who pass on joints, according to research published Thursday. Impact Photography – stock.adobe.com ...

A large, multicenter study published in JAMA Otolaryngology -- Head & Neck Surgery revealed that adults with cannabis dependence, known as cannabis use disorder, are 3.5 to 5 times more likely to ...

VIENNA, Va., March 17, 2025--Head and Neck Cancer Registration Study Protocol clears FDA review—in talks with potential partners Interested in commercialization of Multikine.

Source Reference: Bryan ME, et al "Direct comparison of alternative blood-based approaches for early detection and diagnosis of HPV-associated head and neck cancers" Clin Cancer Res 2025; DOI: 10. ...

“This study shows that switches to alternative regimens in patients with head and neck cancer during the 2023 cisplatin/carboplatin drug shortage crisis involved the use of more expensive substitutes ...

In part 2 of this interview, Ravindra Uppaluri, MD, PhD, director of head and neck surgical oncology at Dana-Farber Brigham Cancer Center, lead investigator of the phase 3 KEYNOTE-689 trial ...